The most recent clinicopathological study demonstrated that KRAS-mutant LUAD specimens exhibited higher expression of PD-L1 in malignant cells and of B7-H3, T-cell immunoglobulin mucin family member 3 (TIM3), and indoleamine 2, 3-dioxygenase-1 (IDO-1) in stromal tumor-associated inflammatory cells than wild-type [100]. The gene discussed is KRAS; the disease is neoplasm.